Anti-inflammatory and antitumor metallotherapeutic drugs: reactivity, properties and interactions with biocompatible hosts

Abstract

This project has the purpose of studying metallotherapeutic drugs as strategic field of bioinorganic with multidisciplinary character involving pharmacological and biological aspects. Previous works of our group gave evidences for anti-inflammatory activity of copper and ruthenium metallodrugs with NSAIDs (non-steroidal anti-inflammatory drugs) and for antiproliferative action of diruthenium metallodrugs against C6 cells (rat glioma) - model for glioblastoma multiform (GBM), a type of malignant brain tumor. Promising pharmacological properties of metallo-NSAIDs, mainly diruthenium-NSAIDs (for which our group is pioneer in studies), open good perspectives for broader and detailed studies. Based on these perspectives, the main goal of the present proposal is to continue our studies with the aim of: preparing novel metallo-NSAIDs; improving characterization studies; investigating chemical and physical-chemistry behavior; studying the reactivity of metallo-NSAIDs towards biomolecules; investigating interactions of the metallo-NSAIDs with biocompatible hosts (cyclodextrins, cellulose derivatives and chitosans) to prepare biocompatible organic-bioinorganic hybrid materials. The major purpose is to get a more complete data file that might help us to establish correlations among molecular structure, reactivity and properties aiming to the elucidation of pharmacological and biological activity of these compounds. Additionally, the project includes the study of viability to prepare hybrid materials that can act as carrier and/or drug (sustained or controlled) delivery systems of metallodrugs aiming to potential future applications in the field of health/biomedicine. (AU)